Rain Oncology Inc
Change company Symbol lookup
Select an option...
RAIN Rain Oncology Inc
LQR LQR House Inc
FCX Freeport-McMoRan Inc
XBIO Xenetic Biosciences Inc
TBCPW Thunder Bridge Capital Partners III Equity Warrant Exp 01 Feb 2025 *W EXP 02/01/2025
HGKGY Power Assets Holdings Ltd
ICPT Intercept Pharmaceuticals Inc
KEY KeyCorp
TTWO Take-Two Interactive Software Inc
TOPS Top Ships Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53. The product candidate is being developed in patients with MDM2-dependent cancers. p53 acts as a regulator of various cellular processes. The activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2 binds to p53, thereby inducing degradation and allowing normal cells to function properly. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2-p53 complex, allowing p53 reactivation and subsequent transcription of genes that trigger cancer cell cycle arrest or apoptosis and can be readily measured by increases in the pharmacodynamic marker MIC-1 (GDF15) in the blood.

Closing Price
$0.8618
Day's Change
0.0072 (0.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.8686
Day's Low
0.8401
Volume
(Heavy Day)
Volume:
185,618

10-day average volume:
107,699
185,618

Company Profile

Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53. The product candidate is being developed in patients with MDM2-dependent cancers. p53 acts as a regulator of various cellular processes. The activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2 binds to p53, thereby inducing degradation and allowing normal cells to function properly. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2-p53 complex, allowing p53 reactivation and subsequent transcription of genes that trigger cancer cell cycle arrest or apoptosis and can be readily measured by increases in the pharmacodynamic marker MIC-1 (GDF15) in the blood.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
0.42x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2023
Current Month
705.7K
Previous Month
861.8K
Percent of Float
3.00%
Days to Cover
3.4958 Days

Share Information

RAIN is in a share class of common stock
Float
23.5M
Shares Outstanding
36.4M
Institutions Holding Shares
78
62.76%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Avanish VellankiChmn.
  • Robert DoebelePres.
  • Joy BruceCFO
  • Franklin M. Berger
  • Aaron I. Davis

Address

Insider Trading

During the most recent quarter, 1M shares were bought, and 995K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.